GUFICBIO2023-04-012023-06-30 GUFICBIO2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member GUFICBIO2023-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 509079 GUFICBIO NOTLISTED Gufic Biosciences Limited Equity 2023-04-01 2024-03-31 2023-08-11 2023-08-04 INR Lakhs First quarter 14:30:00 17:10:00 2023-08-11 2023-08-11 Not applicable Single segment The Company's business activity falls within a single operating segment i.e. Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Standalone 1950202000.00 8812000.00 1959014000.00 803831000.00 160624000.00 3944000.00 233730000.00 40727000.00 42363000.00 393304000.00 1678523000.00 280491000.00 0.00 280491000.00 65000000.00 9262000.00 74262000.00 0.00 206229000.00 0.00 0.00 0.00 0.00 206229000.00 0.00 206229000.00 0.00 0.00 96945000.00 1 2.13 2.13 0.00 0.00 2.13 2.13 0.00 0.00 0.00 1.The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. 2.The above results for the quarter ended June 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 11, 2023. The Statutory Auditors have carried out review of the results for quarter ended June 30, 2023. 3.The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. 4.The Company have incorporated Gufic UK Limited (“GUL”) in the United Kingdom and Gufic Ireland Limited ( GIL ) in Ireland on March 15, 2022 and March 02, 2023, respectively, with the intent of making both the said Companies as its Wholly Owned Subsidiaries. However, the Company have not made any investment in GUL and GIL towards its shares subscription till the quarter ended June 30, 2023. Further GUL and GIL have not yet commenced its business operations till June 30, 2023. Thus the Company is not required to prepare Consolidated Financial Results for the quarter ended June 30, 2023. 5.The figures for the quarter ended March 31, 2023 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to -date figures up to the third quarter ended December 31, 2022 which were subjected to limited review. 6. Previous year/quarters figures have been regrouped/reclassified, wherever necessary. Other Expenses 393304000.00 0.00 0.00